P/E ratio for ChemoCentryx (CCXI)

P/E ratio history for ChemoCentryx from 2012 to 2022

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Biogen BIIB	10.9	-139.67%	🇺🇸 USA
AbbVie ABBV	52.6	-291.24%	🇺🇸 USA
GlaxoSmithKline GSK	11.9	-143.22%	🇬🇧 UK
Bristol-Myers Squibb BMY	12.3	-144.89%	🇺🇸 USA
Johnson & Johnson JNJ	11.7	-142.54%	🇺🇸 USA
Amgen AMGN	23.7	-186.31%	🇺🇸 USA
Pfizer PFE	15.9	-157.97%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	-8.88	-67.72%	🇮🇱 Israel
Merck MRK	64.4	-333.94%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.